Helen Hobbs
Helen Hobbs, M.D., is a professor at the University of Texas Southwestern Medical Center, and a Howard Hughes Medical Institute Investigator, who won a 2016 Breakthrough Prize in Life Sciences and the 2018 Harrington Prize for Innovation in Medicine. She and Jonathan C. Cohen found that people with hypomorphic PCSK9 mutations had lower LDL-cholesterol levels and were almost immune to heart disease. This finding led to the development of a new class of cholesterol-lowering drugs that mimic the effects of the PCSK9 mutations. She and Jonathan Cohen also identified the first genetic risk factor for fatty liver disease, a burgeoning health problem that can lead to cirrhosis and liver cancer. Their laboratory has shown that mutation in PNPLA3 causes accumulation of PNPLA3 on lipid droplets, whi
key person
Breakthrough Prize in Life SciencesDonald SeldinGrand Prix scientifique de la Fondation Lefoulon-DelalandeHeinrich Wieland PrizeJoseph L. GoldsteinList of American Academy of Arts and Sciences members (2006–2019)List of members of the National Academy of MedicineList of members of the National Academy of Sciences (Medical genetics, hematology, and oncology)List of people from TexasPassano FoundationPearl Meister Greengard PrizePfizerRobert J. and Claire Pasarow Foundation Medical Research AwardSchottenstein Prize in Cardiovascular Sciences
Link from a Wikipage to another Wikipage
primaryTopic
Helen Hobbs
Helen Hobbs, M.D., is a professor at the University of Texas Southwestern Medical Center, and a Howard Hughes Medical Institute Investigator, who won a 2016 Breakthrough Prize in Life Sciences and the 2018 Harrington Prize for Innovation in Medicine. She and Jonathan C. Cohen found that people with hypomorphic PCSK9 mutations had lower LDL-cholesterol levels and were almost immune to heart disease. This finding led to the development of a new class of cholesterol-lowering drugs that mimic the effects of the PCSK9 mutations. She and Jonathan Cohen also identified the first genetic risk factor for fatty liver disease, a burgeoning health problem that can lead to cirrhosis and liver cancer. Their laboratory has shown that mutation in PNPLA3 causes accumulation of PNPLA3 on lipid droplets, whi
has abstract
Helen Hobbs, M.D., is a profes ...... Board of Directors at Pfizer.
@en
Link from a Wikipage to an external page
Wikipage page ID
48,504,761
page length (characters) of wiki page
Wikipage revision ID
1,002,491,205
Link from a Wikipage to another Wikipage
wikiPageUsesTemplate
subject
hypernym
sameAs
comment
Helen Hobbs, M.D., is a profes ...... PNPLA3 on lipid droplets, whi
@en
label
Helen Hobbs
@en